n Cardiovascular Journal of South Africa - EUROPA : clinical benefits, clinical promise : drug trends in cardiology




Extracted from text ... 147 EUROPA: clinical benefits, clinical promise Should we consider the routine administration of ACE inhibitors such as perindopril in all people with coronary artery disease (CAD)? 'Yes', said Professor Willem Remme of the 'Sticares' Cardiovascular Research Institute, Rhoon, the Netherlands, as he concluded his presentation on the EUROPA (EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease) study to doctors around South Africa. The EUROPA1 study was designed to assess whether the long-term administration of perindopril, added to standard preventative therapy, would reduce cardiovascular events in a broad spectrum of patients with definite evidence of ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error